Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

286
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
286
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

183
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
183
Drug Therapy01:28

Drug Therapy

83
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
83
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

294
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
294
Bipolar Disorder01:30

Bipolar Disorder

117
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
117
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

226
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
226

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Organizational Stressors, Burnout, and Mental Health Outcomes Among Local Government Employees During Disaster Response.

Journal of occupational and environmental medicine·2026
Same author

Effect of Social Support on Suicide Risk among Posttraumatic Stress Disorder, Depressive, and Comorbid Symptom Groups in Elderly Living Alone in Korea.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same author

Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.

Therapeutic advances in psychopharmacology·2026
Same author

Deep neural network-based analysis of voice biomarkers for monitoring treatment response in adolescent major depressive disorder.

Communications medicine·2026
Same author

Korean Medication Algorithm Project for Depressive Disorder 2025: Comparisons with Other Treatment Guidelines.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same author

Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease: Clinical Perspectives.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Psychosis in a 47,XXX Adolescent: Clinical Management and Multidisciplinary Follow-up.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Guanfacine as a Treatment Option for Persistent Mental Restlessness and Deliberate Self-harm Thoughts in a Patient with Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Borderline Personality Disorder, and Post-traumatic Stress Disorder: Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Delirious Mania with Mild Encephalitis and a Reversible Splenial Lesion Successfully Treated with Electroconvulsive Therapy: A Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Time-limited Moderating Effect of Neuroticism on the Cortisol-Depression Relationship after Physical Injury.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Antibiotic-induced Microbiome Depletion Selectively Reduces Baseline Hypothalamic Oxytocin Signaling without Affecting MDMA-induced Oxytocin Response in Rats.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
Same journal

Early Individualized Psychological Intervention Using Virtual Reality-assisted Decision System Reduces Decisional Conflict in Patients with Pulmonary Nodules: A Randomized Controlled Trial.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2026
See all related articles

Related Experiment Video

Updated: Aug 12, 2025

Developing a Rat Model for Bipolar Disorder
04:44

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

415

Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines.

Jong-Hyun Jeong1,2, Won-Myong Bahk1, Young Sup Woo1

  • 1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology
|January 26, 2023
PubMed
Summary
This summary is machine-generated.

The Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) aligns with global guidelines for initial mania treatment. KMAP-BP 2022 uniquely favors combination therapy for specific severe bipolar disorder presentations.

Keywords:
AlgorithmBipolar disorderGuidelineKMAP-BP 2022Pharmacotherapy

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.7K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

761

Related Experiment Videos

Last Updated: Aug 12, 2025

Developing a Rat Model for Bipolar Disorder
04:44

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

415
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.7K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

761

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Practice Guidelines

Background:

  • Bipolar disorder treatment requires updated guidelines.
  • Global variations in treatment recommendations exist.
  • The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) provides specific recommendations.

Purpose of the Study:

  • To compare KMAP-BP 2022 recommendations with other recent global bipolar disorder treatment guidelines.
  • To identify similarities and differences in treatment strategies.
  • To evaluate the KMAP-BP 2022's alignment with international standards.

Main Methods:

  • Review of six recent global bipolar disorder treatment guidelines.
  • Comparative analysis of KMAP-BP 2022 with reviewed guidelines.
  • Focus on initial treatment, specific phases, and combination therapies.

Main Results:

  • No significant differences in initial mania treatment recommendations across guidelines.
  • KMAP-BP 2022 uniquely recommends mood stabilizer (MS) + atypical antipsychotic (AAP) combination therapy as a first-line choice for psychotic mania, mixed mania, and psychotic depression.
  • Aripiprazole, quetiapine, and olanzapine are consistently recommended first-line AAPs; newer AAPs and lamotrigine are also highlighted.
  • Lithium and valproic acid are common MSs across all phases.

Conclusions:

  • KMAP-BP 2022 guidelines reflect current research and global trends in bipolar disorder pharmacotherapy.
  • The algorithm's distinct emphasis on combination therapy for severe presentations warrants attention.
  • KMAP-BP 2022 offers a valuable, updated perspective on bipolar disorder management.